Dr Li on the Investigation of BDC-1001 in HER2-expressing Solid Tumors

Bob T. Li, MD, PhD, MPH, discusses the results of a phase 1/2 study of the first-in-class immune-stimulating antibody conjugate BDC-1001 in patients with advanced HER2-expressing solid tumors.

Related Keywords

China ,Bobt Li , ,Bobst International Center ,Memorial Sloan Kettering Cancer Center ,Thoracic Liquid Biopsy Program ,